These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12852985)

  • 1. [Circadian variations of dihydropyrimidine dehydrogenase (DPD) activity in oral mucosa of healthy volunteers].
    Barrat MA; Renée N; Mormont MC; Milano G; Levi F
    Pathol Biol (Paris); 2003 Jun; 51(4):191-3. PubMed ID: 12852985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dihydropyrimidine deshydrogenase (DPD): rhythm and consequences].
    Barrat-Petit MA; Naulin-Ifi C; Mahler P; Milano G
    Pathol Biol (Paris); 2005 Jun; 53(5):261-4. PubMed ID: 15939134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics.
    Milano G; Chamorey AL
    Chronobiol Int; 2002 Jan; 19(1):177-89. PubMed ID: 11962674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized Chronomodulated 5-Fluorouracil Treatment: A Physiologically-Based Pharmacokinetic Precision Dosing Approach for Optimizing Cancer Therapy.
    Marok FZ; Wojtyniak JG; Selzer D; Dallmann R; Swen JJ; Guchelaar HJ; Schwab M; Lehr T
    Clin Pharmacol Ther; 2024 Jun; 115(6):1282-1292. PubMed ID: 38264789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers.
    Jacobs BA; Deenen MJ; Pluim D; van Hasselt JG; Krähenbühl MD; van Geel RM; de Vries N; Rosing H; Meulendijks D; Burylo AM; Cats A; Beijnen JH; Huitema AD; Schellens JH
    Br J Clin Pharmacol; 2016 Sep; 82(3):706-16. PubMed ID: 27161955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circadian variation in intestinal dihydropyrimidine dehydrogenase (DPD) expression: a potential mechanism for benefits of 5FU chrono-chemotherapy.
    Abolmaali K; Balakrishnan A; Stearns AT; Rounds J; Rhoads DB; Ashley SW; Tavakkolizadeh A
    Surgery; 2009 Aug; 146(2):269-73. PubMed ID: 19628084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits.
    Milano G; Etienne MC
    Ther Drug Monit; 1996 Aug; 18(4):335-40. PubMed ID: 8857547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a bolus injection of 5-fluorouracil on dihydropyrimidine dehydrogenase activity in rats receiving continuous infusion of 5-fluorouracil.
    Kobuchi S; Hayashi A; Taniguchi M; Ito Y; Tamura T; Sakaeda T
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):517-23. PubMed ID: 27417318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
    Adjei AA; Reid JM; Diasio RB; Sloan JA; Smith DA; Rubin J; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Atherton P; Ames MM; Erlichman C
    J Clin Oncol; 2002 Mar; 20(6):1683-91. PubMed ID: 11896120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circadian variation of dihydropyrimidine dehydrogenase mRNA expression in leukocytes and serum cortisol levels in patients with advanced gastrointestinal carcinomas compared to healthy controls.
    Raida M; Kliche KO; Schwabe W; Häusler P; Clement JH; Behnke D; Höffken K
    J Cancer Res Clin Oncol; 2002 Feb; 128(2):96-102. PubMed ID: 11862480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dihydropyrimidine dehydrogenase activity in 150 healthy Japanese volunteers and identification of novel mutations.
    Ogura K; Ohnuma T; Minamide Y; Mizuno A; Nishiyama T; Nagashima S; Kanamaru M; Hiratsuka A; Watabe T; Uematsu T
    Clin Cancer Res; 2005 Jul; 11(14):5104-11. PubMed ID: 16033824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I pharmacological study of continuous chronomodulated capecitabine treatment.
    Roosendaal J; Jacobs BAW; Pluim D; Rosing H; de Vries N; van Werkhoven E; Nuijen B; Beijnen JH; Huitema ADR; Schellens JHM; Marchetti S
    Pharm Res; 2020 May; 37(5):89. PubMed ID: 32382808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels.
    Jiang H; Lu J; Ji J
    Br J Pharmacol; 2004 Feb; 141(4):616-23. PubMed ID: 14744810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?
    Milano G; McLeod HL
    Eur J Cancer; 2000 Jan; 36(1):37-42. PubMed ID: 10741292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.
    Ciccolini J; Mercier C; Blachon MF; Favre R; Durand A; Lacarelle B
    J Clin Pharm Ther; 2004 Aug; 29(4):307-15. PubMed ID: 15271097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer.
    Kobuchi S; Kuwano S; Imoto K; Okada K; Nishimura A; Ito Y; Shibata N; Takada K
    Biopharm Drug Dispos; 2013 Oct; 34(7):365-76. PubMed ID: 23836081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
    Ogura K
    Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Population study of dihydropyrimidine dehydrogenase in cancer patients].
    Etienne MC; Milano G; Renée N; Lagrange JL; Dassonville O; Thyss A; Schneider M; François E; Fleming R; Demard F
    Bull Cancer; 1995 Sep; 82(9):705-10. PubMed ID: 8535028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved analysis of 5-Fluorouracil and 5,6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling.
    Di Paolo A; Danesi R; Ciofi L; Vannozzi F; Bocci G; Lastella M; Amatori F; Martelloni BM; Ibrahim T; Amadori D; Falcone A; Del Tacca M
    Ther Drug Monit; 2005 Jun; 27(3):362-8. PubMed ID: 15905808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.